Universal Registration Document

Overview

The report presents GenSight Biologics as a clinical-stage gene therapy company focused on severe retinal neurodegenerative diseases. It reports continued GS010 development through Phase III trials and describes GS030's ongoing Phase I/II program for retinitis pigmentosa. The document also records financing transactions intended to fund GS010 clinical and pharmaceutical development, regulatory filings, and commercial preparation. Employee and corporate responsibility disclosures cover workforce composition, health and safety, training, and diversity.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2018
Period: 1 January 2019 – 30 June 2019
Publication date: 20 December 2019
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services